- Report
- March 2025
- 175 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- March 2025
- 293 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- February 2025
- 262 Pages
Global
From €5201EUR$5,450USD£4,358GBP
- Report
- March 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- July 2024
- 100 Pages
Global
From €3579EUR$3,750USD£2,999GBP
- Report
- May 2024
- 185 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- July 2023
- 253 Pages
Europe
From €3293EUR$3,450USD£2,759GBP
- Report
- April 2018
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- August 2023
- 96 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- August 2023
- 96 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- September 2024
- 300 Pages
Global
From €2534EUR$2,655USD£2,123GBP
The Blood Component market is a subset of the biopharmaceutical industry that focuses on the production and distribution of blood components, such as red blood cells, platelets, and plasma. These components are used to treat a variety of medical conditions, including anemia, cancer, and trauma. The market is highly regulated, with stringent safety and quality standards in place to ensure the safety of the products.
The Blood Component market is a highly competitive space, with a number of companies vying for market share. Some of the major players in the market include Grifols, CSL Behring, Octapharma, Kedrion, and Biotest. Show Less Read more
